ADC Therapeutics SA (ADCT)
USD 1.91
(-10.33%)
USD 1.91
(-10.33%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -2.94 USD | -47.74% |
| 2022 | -1.99 USD | 33.67% |
| 2021 | -3.00 USD | 20.42% |
| 2020 | -3.77 USD | -116.67% |
| 2019 | -1.74 USD | 24.02% |
| 2018 | -2.29 USD | -49.67% |
| 2017 | -1.53 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.56 USD | 45.63% |
| 2024 Q2 | -0.38 USD | 32.14% |
| 2023 Q2 | -0.58 USD | 21.62% |
| 2023 Q3 | -0.58 USD | 0.0% |
| 2023 Q1 | -0.74 USD | -146.67% |
| 2023 FY | - USD | -47.74% |
| 2023 Q4 | -1.03 USD | -77.59% |
| 2022 Q4 | -0.30 USD | 53.85% |
| 2022 Q3 | -0.65 USD | 22.62% |
| 2022 Q2 | -0.84 USD | -281.82% |
| 2022 FY | - USD | 33.67% |
| 2022 Q1 | -0.22 USD | 51.11% |
| 2021 FY | - USD | 20.42% |
| 2021 Q3 | -0.93 USD | 2.11% |
| 2021 Q1 | -0.67 USD | 8.22% |
| 2021 Q4 | -0.45 USD | 51.61% |
| 2021 Q2 | -0.95 USD | -41.79% |
| 2020 Q1 | -0.68 USD | -41.67% |
| 2020 FY | - USD | -116.67% |
| 2020 Q2 | -2.01 USD | -195.59% |
| 2020 Q3 | -0.29 USD | 85.57% |
| 2020 Q4 | -0.73 USD | -151.72% |
| 2019 Q4 | -0.48 USD | -11.63% |
| 2019 Q3 | -0.43 USD | -34.37% |
| 2019 Q2 | -0.32 USD | 39.62% |
| 2019 Q1 | -0.53 USD | 82.79% |
| 2019 FY | - USD | 24.02% |
| 2018 Q3 | -0.57 USD | 0.87% |
| 2018 Q2 | -0.57 USD | 0.0% |
| 2018 FY | - USD | -49.67% |
| 2018 Q1 | -0.57 USD | 0.0% |
| 2018 Q4 | -3.08 USD | -441.3% |
| 2017 FY | - USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Alto Neuroscience, Inc. | -1.35 USD | -117.778% |
| Annovis Bio, Inc. | -6.23 USD | 52.809% |
| Biohaven Pharmaceutical Holding Company Ltd. | -5.73 USD | 48.691% |
| Ginkgo Bioworks Holdings, Inc. | -18.37 USD | 83.996% |
| Nuvation Bio Inc. | -0.35 USD | -740.0% |
| Nuvation Bio Inc. | -0.35 USD | -740.0% |
| Arcus Biosciences, Inc. | -4.15 USD | 29.157% |
| Theriva Biologics, Inc. | -28.49 USD | 89.681% |
| Zymeworks Inc. | -1.72 USD | -70.93% |